Any deviation can impact peptide solubility and stability
Heres what to watch for: Increased Energy and Alertness Many patients feel less sluggish within 13 days
Allison Whitten AstraZeneca reports mixed Phase 3 results across oncology and rare disease AstraZeneca reported mixed late-stage clinical results, with its Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin meeting its primary endpoint in patients with previously treated advanced gastric cancer, while rare disease therapy Ultomiris missed the primary endpoint in a Phase 3 trial for thrombotic microangiopathy following haematopoietic stem cell transplantation (HSCT-TMA)
Most people start feeling more energised within two to three days of their first injection
BENEFITS/ CLINICAL TRIALS Cagrilintide has demonstrated effective results in both monotherapy, as well as, more prominently, in combination with the GLP-1 receptor agonist, Semaglutide (referred to as CagriSema)
Motus showed a high fat-to-lean loss ratio, with approximately 87% of the weight lost from fat versus lean mass in its trial population
